Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LOXO

Loxo Oncology (LOXO) Stock Price, News & Analysis

Loxo Oncology logo

About Loxo Oncology Stock (NASDAQ:LOXO)

Advanced Chart

Key Stats

Today's Range
$234.66
$234.66
50-Day Range
N/A
52-Week Range
$101.70
$234.93
Volume
400 shs
Average Volume
565,561 shs
Market Capitalization
$7.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Receive LOXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Loxo Oncology and its competitors with MarketBeat's FREE daily newsletter.

LOXO Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Q3 2024 Eli Lilly and Co Earnings Call
See More Headlines

LOXO Stock Analysis - Frequently Asked Questions

Loxo Oncology Inc (NASDAQ:LOXO) released its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.15. The biopharmaceutical company had revenue of $42.60 million for the quarter, compared to the consensus estimate of $32.36 million. Loxo Oncology had a negative trailing twelve-month return on equity of 16.42% and a negative net margin of 43.49%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Loxo Oncology investors own include Meta Platforms (META), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), GW Pharmaceuticals (GWPH) and Micron Technology (MU).

Company Calendar

Last Earnings
8/09/2018
Today
5/23/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LOXO
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-148,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.30 million
Price / Cash Flow
N/A
Book Value
$12.63 per share
Price / Book
18.58

Miscellaneous

Free Float
N/A
Market Cap
$7.18 billion
Optionable
Optionable
Beta
2.51
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:LOXO) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners